Elisabeth M. M. Gardiner
Keine laufenden Positionen mehr
Profil
Elisabeth M.
M.
Gardiner worked as a Director-Physiology Discovery at aTyr Pharma, Inc. and as a Principal at Kalypsys, Inc. She was also a Vice President-Discovery Biology at Kinnate Biopharma, Inc. from 2018 to 2020.
Gardiner served as VP-Translational Medicine & Patrick Simms at Aravive, Inc. from 2020 to 2022.
She holds a doctorate degree from the University of Wisconsin.
Ehemalige bekannte Positionen von Elisabeth M. M. Gardiner
Unternehmen | Position | Ende |
---|---|---|
ARAVIVE, INC. | Corporate Officer/Principal | 01.04.2022 |
KINNATE BIOPHARMA INC. | Corporate Officer/Principal | 01.06.2020 |
Kalypsys, Inc.
Kalypsys, Inc. Pharmaceuticals: MajorHealth Technology Kalypsys, Inc. discovered and developed novel, first-in-class therapeutic agents to address unmet medical needs in respiratory and inflammatory diseases. The firm advanced its proprietary lead program, a novel, non-corticosteroid small molecule formulated for intranasal delivery, into clinical proof of concept studies. The company was founded by Pratik Shah, Jeremy S. Caldwell, Randall W. King, Kevin D. Lustig, Peter G. Schultz and Robert Downs in 2001 and was headquartered in Solana Beach, CA. | Corporate Officer/Principal | - |
ATYR PHARMA, INC. | Corporate Officer/Principal | - |
Ausbildung von Elisabeth M. M. Gardiner
University of Wisconsin | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
ATYR PHARMA, INC. | Health Technology |
ARAVIVE, INC. | Health Technology |
Private Unternehmen | 2 |
---|---|
Kalypsys, Inc.
Kalypsys, Inc. Pharmaceuticals: MajorHealth Technology Kalypsys, Inc. discovered and developed novel, first-in-class therapeutic agents to address unmet medical needs in respiratory and inflammatory diseases. The firm advanced its proprietary lead program, a novel, non-corticosteroid small molecule formulated for intranasal delivery, into clinical proof of concept studies. The company was founded by Pratik Shah, Jeremy S. Caldwell, Randall W. King, Kevin D. Lustig, Peter G. Schultz and Robert Downs in 2001 and was headquartered in Solana Beach, CA. | Health Technology |
Kinnate Biopharma, Inc.
Kinnate Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Kinnate Biopharma, Inc. operates as a biopharmaceutical company engaged in the research and development of Kinnate Discovery Engine that targets genomic drivers of cancer. The company was founded by Stephen W. Kaldor and Eric A. Murphy in January 2018 and is headquartered in San Diego, CA. | Health Technology |